For: | Singh A, Sohal A, Batta A. GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis. World J Gastroenterol 2024; 30(48): 5205-5211 [PMID: 39735270 DOI: 10.3748/wjg.v30.i48.5205] |
---|---|
URL: | https://www.wjgnet.com/1949-8462/full/v30/i48/5205.htm |
Number | Citing Articles |
1 |
Shujun Li, Nanqu Huang, Mei Wang, Wendi Huang, Yong Luo, Juan Huang. GLP-1R in diabetes mellitus: from basic discovery to therapeutics development. Frontiers in Pharmacology 2025; 16 doi: 10.3389/fphar.2025.1610512
|
2 |
Yilmaz Gunes. A brief approach to hypertension in type 2 diabetes mellitus. Exploration of Endocrine and Metabolic Diseases 2025; doi: 10.37349/eemd.2025.101422
|
3 |
Xing Wan, Jingyuan Ma, He Bai, Xuyang Hu, Yanna Ma, Mingjian Zhao, Jifeng Liu, Zhijun Duan. Drug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs. Biomolecules 2025; 15(1): 140 doi: 10.3390/biom15010140
|
4 |
Xinyi Zhang, Nanqin Peng, Xiaoyue Zhang, Zicheng Zhu, Yan Miao, Yuting Wu, Jitao Ling, Chen Li, Wenli Gu, Jing Zhang, Abudukeremu Ayiguli, Ziheng Zheng, Peng Yu, Xiao Liu. Association of glucagon-like peptide-1 receptor agonists with atrial fibrillation, cardiac arrest, and ventricular fibrillation: Casual evidence from a drug target Mendelian randomization. Diabetology & Metabolic Syndrome 2025; 17(1) doi: 10.1186/s13098-025-01712-w
|
5 |
Adam Vašura, Evžen Machytka, Marek Bužga, Jitka Macháčková, Jan Král. The significance of metabolism-associated steatotic liver disease and its treatment. Vnitřní lékařství 2025; 71(1): 29 doi: 10.36290/vnl.2025.005
|